¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
ȳó¼ºÇѼ±¿°(HS)ÀÇ Ä¡·á »óȲÀº Ä¡·á ¿É¼ÇÀÇ »ó´çÇÑ Áøº¸·Î ºü¸£°Ô ÁøÈÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ º¸°í¼´Â ÁÖ¿ä KOL ÀλçÀÌÆ®¸¦ ¹ÙÅÁÀ¸·Î HSÀÇ ÇöÀç ¹× ¹Ì·¡ Ä¡·á »óȲÀ» Á¾ÇÕÀûÀ¸·Î ºÐ¼®ÇÕ´Ï´Ù. ƯÈ÷, »ý¹°ÇÐÀû Á¦Á¦ Ä¡·áÀÇ Ã¹ ¹ø° ¼±Åà ¾à¹°·Î¼ AbbVieÀÇ Humira(adalimumab)ÀÇ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒ, ¾Æ´Þ¸®¹«¸¿ÀÌ È¿°ú°¡ ¾ø°Å³ª °ßµô ¼ö¾ø´Â ȯÀÚ¿¡ ´ëÇÑ NovartisÀÇ Cosentyx(Sekkinumab)ÀÇ À¯¸Á¼º ¹× UCBÀÇ Bimzelx(bimekizumab))ÀÇ »õ·Î¿î °¡´É¼ºÀ» °Á¶ÇÕ´Ï´Ù. ¶ÇÇÑ HS Ä¡·á ¾Ë°í¸®ÁòÀÇ ÁøÇà »óȲ°ú ÀÓ»ó Áø·á ¹× ÀǾàÇ° °³¹ß¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ºÐ¼®Çß½À´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ ´äº¯À» ¾òÀ» ¼ö ÀÖ´Â ÁÖ¿ä Áú¹® :
- TNF ¾ïÁ¦Á¦(AbbVieÀÇ Humira(adalimumab)¿Í Johnson & Johnson/Merck & Co.ÀÇ Remicade(infliximab) µî)°¡ ÇöÀçÀÇ HS Ä¡·á¿¡ ÀÖ¾î¼ÀÇ ¿ªÇÒÀº ¹«¾ùÀΰ¡? ¶ÇÇÑ ¾î¶² º¯È°¡ ¿¹»óµÇ´Â°¡?
- ¾Æ´Þ¸®¹«¸¿ÀÌ È¿°ú°¡ ¾ø°Å³ª °ßµô ¼ö ¾ø´Â ȯÀÚ¿¡ ´ëÇÑ NovartisÀÇ Cosentyx(secukinumab)¿Í °°Àº 2Â÷ Ä¡·á ¿É¼ÇÀº ¾ó¸¶³ª È¿°úÀûÀΰ¡?
- HS Ä¡·á¿¡¼ UCB»çÀÇ Bimzelx(Bimekizumab)ÀÇ »õ·Î¿î °¡´É¼º°ú 3»ó ÀÓ»ó½ÃÇè µ¥ÀÌÅÍ´Â ¹«¾ùÀ» ½Ã»çÇմϱî?
- HS¿¡ ´ëÇÑ ÁÖ¿ä »ý¹°ÇÐÀû Á¦Á¦ÀÇ È¿´É ¹× ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀº?
- »õ·Î¿î Ä¡·á¹ýÀÇ µµÀÔÀ¸·Î Ä¡·á Æз¯´ÙÀÓÀº ¾î¶»°Ô ÁøÈÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â°¡?
- HSÀÇ ÇöÀç ¹× ¹Ì·¡ °ü¸® Àü·«¿¡ ´ëÇØ ÁÖ¿ä KOL(Key Opinion Leader)Àº ¾î¶² °ßÇظ¦ Á¦½ÃÇմϱî?
- HSÀÇ ±âÁ¸ Ä¡·á¹ý°ú »õ·Î¿î Ä¡·á¹ýÀÇ »ç¿ë¿¡¼ ¾î¶² º¯È°¡ ¿¹»óµÇ´Â°¡?
- HS °ü¸®¿¡¼ ÀÓ»ó Áø·á ¹× ÀǾàÇ° °³¹ß¿¡ ÀÖ¾î¼ ÀÌ·¯ÇÑ ÁøÀüÀº ¾î¶² Àü·«Àû Àǹ̸¦ °¡Áö´Â°¡?
º» º¸°í¼ÀÇ Á¶»ç ´ë»ó ÁÖ¿ä ºê·£µå
- Humira(adalimumab)
- Cosentyx(secukinumab)
- Bimzelx(bimekizumab)
- Izokibep
- Sonelokimab
- Povorcitinib
- Rinvoq(upadacitinib)
- Opzelura(ruxolitinib)
- Brepocitinib
- Sotyktu(deucravacitinib)
- Lutikizumab
- Spevigo(spesolimab)
- Orismilast
- Orismilast
|
- Amlitelimab
- SAR442970
- Eltrekibart
- MC2-32
- Remibrutinib
- MAS825
- lys006
- Iscalimab
- Ianalumab
- Tavneos(avacopan)
- KT-474
- PTM-001
|
Á¶»ç ´ë»ó ±â¾÷
- AbbVie
- Amgen
- Novartis
- Lilly
- Sanofi
- UCB
- Merck & Co.
- Bristol Myers Squibb
- Incyte
- Boehringer Ingelheim
|
- Affibody
- Johnson & Johnson
- ACELYRIN
- Moonlake Immunotherapeutics
- UNION Therapeutics
- Phoenicis Therapeutics
- Kymera Therapeutics
- Priovant Therapeutics
- MC2 Therapeutics
|
¸ñÂ÷
ÁÖ¿ä ¿ä¾à
ÇöÀç ¹× ¹Ì·¡ÀÇ Ä¡·á ¾Ë°í¸®Áò
Á¶»ç ¸ñÀû
TNF ¾ïÁ¦Á¦
- ½ÂÀÎ ÀǾàÇ°
- Humira(adalimumab; AbbVie), Remicade(infliximab; Johnson & Johnson/Merck & Co.)
IL-17 ¾ïÁ¦Á¦
- ½ÂÀÎ ÀǾàÇ°
- Cosentyx(secukinumab; Novartis)
- Bimzelx(bimekizumab; UCB)
- ÆÄÀÌÇÁ¶óÀÎ ÀǾàÇ°
- Izokibep(Affibody/ACELYRIN)
- Sonelokimab(MoonLake Immunotherapeutics)
JAK/TYK2 ¾ïÁ¦Á¦
- ÆÄÀÌÇÁ¶óÀÎ ÀǾàÇ°
- Povorcitinib(INCB54707; Incyte)
- Rinvoq(upadacitinib; AbbVie)
- Opzelura(ruxolitinib; Incyte)
- Brepocitinib(Priovant Therapeutics)
- Sotyktu(deucravacitinib; Incyte)
±âŸ ÀÛ¿ë ¸ÞÄ¿´ÏÁò
- ÆÄÀÌÇÁ¶óÀÎ ÀǾàÇ°
- Lutikizumab(ABT-981; AbbVie)
- Spevigo(spesolimab; Boehringer Ingelheim)
- Orismilast(UNION Therapeutics)
- Amlitelimab¡¤SAR442970(Sanofi)
- Eltrekibart(LY3041658; Lilly)
- MC2-32(RGRN-305; MC2 Therapeutics)
- Remibrutinib, MAS825, lys006, iscalimab, ianalumab(Novartis)
- Tavneos(avacopan; Amgen)
- KT-474(Kymera Therapeutics/Sanofi)
- PTM-001(Phoenicis Therapeutics)
¹Ì·¡ÀÇ Ä¡·á µ¿Çâ
ºÎ·Ï
AJY 24.08.19
The treatment landscape for hidradenitis suppurativa (HS) is rapidly evolving with significant advancements in therapeutic options. Insights from leading KOLs provide a comprehensive review of the current and future treatment landscape for HS, highlighting the pivotal role of AbbVie's Humira (adalimumab) as the primary first-line biologic treatment, the promise of Novartis' Cosentyx (secukinumab) for patients who do not respond to or cannot tolerate adalimumab, and the emerging potential of UCB's Bimzelx (bimekizumab). Explore the evolving HS treatment algorithms and the implications for clinical practice and drug development.
Key questions answered:
- What is the current role of TNF inhibitors, such as Abbvie's Humira (adalimumab) and Johnson & Johnson/Merck & Co.'s Remicade (infliximab), in the treatment of HS? What changes are anticipated in their usage?
- How effective are secondary treatment options like Novartis' Cosentyx (secukinumab) for patients who do not respond to or cannot tolerate adalimumab?
- What is the emerging potential of UCB's Bimzelx (bimekizumab) in the HS treatment landscape, and what do the Phase III trial data suggest?
- What are the key efficacy and safety profiles of the leading biologic treatments for HS?
- How are treatment paradigms expected to evolve with the introduction of new therapies?
- What insights do leading Key Opinion Leaders (KOLs) provide on the current and future management strategies for HS?
- What are the anticipated changes in the usage of existing and emerging treatments for HS?
- What are the strategic implications of these developments for clinical practice and drug development in HS management?
Key brands covered in this report:
- Humira (adalimumab)
- Cosentyx (secukinumab)
- Bimzelx (bimekizumab)
- Izokibep
- Sonelokimab
- Povorcitinib
- Rinvoq (upadacitinib)
- Opzelura (ruxolitinib)
- Brepocitinib
- Sotyktu (deucravacitinib)
- Lutikizumab
- Spevigo (spesolimab)
- Orismilast
|
- Amlitelimab
- SAR442970
- Eltrekibart
- MC2-32
- Remibrutinib
- MAS825
- lys006
- Iscalimab
- Ianalumab
- Tavneos (avacopan)
- KT-474
- PTM-001
|
Companies:
- AbbVie
- Amgen
- Novartis
- Lilly
- Sanofi
- UCB
- Merck & Co.
- Bristol Myers Squibb
- Incyte
- Boehringer Ingelheim
|
- Affibody
- Johnson & Johnson
- ACELYRIN
- Moonlake Immunotherapeutics
- UNION Therapeutics
- Phoenicis Therapeutics
- Kymera Therapeutics
- Priovant Therapeutics
- MC2 Therapeutics
|
Table of Contents
Executive summary
Current and future treatment algorithm
Research objectives
TNF inhibitors
- Approved drugs
- Humira (adalimumab; AbbVie) and Remicade (infliximab; Johnson & Johnson/Merck & Co.)
IL-17 inhibitors
- Approved drugs
- Cosentyx (secukinumab; Novartis)
- Bimzelx (bimekizumab; UCB)
- Pipeline drugs
- Izokibep (Affibody/ACELYRIN)
- Sonelokimab (MoonLake Immunotherapeutics)
JAK/TYK2 inhibitors
- Pipeline drugs
- Povorcitinib (INCB54707; Incyte)
- Rinvoq (upadacitinib; AbbVie)
- Opzelura (ruxolitinib; Incyte)
- Brepocitinib (Priovant Therapeutics)
- Sotyktu (deucravacitinib; Bristol Myers Squibb)
Other mechanisms of action
- Pipeline drugs
- Lutikizumab (ABT-981; AbbVie)
- Spevigo (spesolimab; Boehringer Ingelheim)
- Orismilast (UNION Therapeutics)
- Amlitelimab and SAR442970 (Sanofi)
- Eltrekibart (LY3041658; Lilly)
- MC2-32 (RGRN-305; MC2 Therapeutics)
- Remibrutinib, MAS825, LYS006, iscalimab and ianalumab (Novartis)
- Tavneos (avacopan; Amgen)
- KT-474 (Kymera Therapeutics/Sanofi)
- PTM-001 (Phoenicis Therapeutics)
Future treatment trends
Appendix
- KOL details
- KOLs from the USA
- KOLs from Europe